secwatch.observer — SEC 8-K summary
======================================

Issuer:     10x Genomics, Inc. (TXG)
CIK:        0001770787
Form:       8-K
Filed at:   2022-11-02T23:59:59+00:00
Accession:  0001770787-22-000053
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

10x Genomics Q3 revenue up 5% to $131.1M but net loss widens to $41.9M
----------------------------------------------------------------------

- Revenue $131.1M (+5% YoY, +14% QoQ); gross margin 77% (down from 80% in Q3 2021).
- Operating loss $40.0M vs $15.9M YoY; net loss $41.9M vs $17.2M YoY, including $33.5M stock-based compensation.
- FY2022 revenue guidance reaffirmed at $500-520M; cash & equivalents $452.4M at Sep 30, 2022.
- Highlights Xenium in situ platform launch expected later this year and long-read sequencing compatibility.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1770787/000177078722000053/0001770787-22-000053-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1770787/000177078722000053/txg-20221102.htm
  HTML page:      https://secwatch.observer/filing/0001770787-22-000053

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer